Detailed View
ALNY - Alnylam Pharmaceuticals, Inc.
Latest filing: 2026-09-30 | Reporting: gaap
Market Cap
21,162,137,600
Adj EBIT (TTM)
1,285,122,000
Enterprise Value
19,407,797,600
Last Price
158
Earnings Yield
6.62%
Return on Capital
21.67%
Capital
5,931,666,000
1Y Price Chart
Last Price: $158.00
1Y Change: -64.85%
As of 2026-11-02 | 1Y Change: -64.85%
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-09-30 | 10-Q | 2026 | 1,458,086,000 | 345,798,000 |
| 2026-06-30 | 10-Q | 2026 | 1,290,948,000 | 231,441,000 |
| 2026-03-31 | 10-Q | 2026 | 1,167,175,000 | 268,636,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 1,097,033,000 | 131,718,000 |
| 2025-09-30 | 10-Q | 2025 | 1,249,026,000 | 367,982,000 |
| 2025-06-30 | 10-Q | 2025 | 773,689,000 | -16,199,000 |
| 2025-03-31 | 10-Q | 2025 | 594,189,000 | 18,077,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 593,166,000 | -105,159,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.